Rather & Kittrell’s Gilead Sciences GILD Stock Holding History

Rather & Kittrell’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,787	Closed	-$129K	–	146
2021 Q4	$129K	Buy	+1,787	New	+$123K	0.11%	76

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rather & Kittrell's GILD Position: Q1 2022 in Review

Rather & Kittrell sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 1,787 shares — an estimated $129K sold.

Rather & Kittrell first reported a position in GILD in Q4 2021 and held it in 1 quarter. The position peaked at $129K in Q4 2021. 1,600 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

Rather & Kittrell reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
Rather & Kittrell sold 1,787 Gilead Sciences shares in Q1 2022, an estimated $129K.
Rather & Kittrell first reported a position in Gilead Sciences in Q4 2021 and held it in 1 quarter.
Rather & Kittrell's Gilead Sciences position peaked at $129K in Q4 2021.
1,600 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Rather & Kittrell's 13F filing for Q1 2022, filed 10 May 2022.